Anti-CDKN2A/p14ARF antibody [EPR17878]
- 20ul selling size
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(16 Publications)
Rabbit Recombinant Monoclonal p14ARF antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 16 publications.
View Alternative Names
CDKN2, MLM, CDKN2A, Tumor suppressor ARF, Alternative reading frame, Cyclin-dependent kinase inhibitor 2A, p14ARF, ARF
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody [EPR17878] (AB185620)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervix adenocarcinoma) cells transfected with CDKN2A/p14ARF or empty vector, labeling CDKN2A/p14ARF with ab185620 at 1/250 dilution, followed by Goat Anti-Rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution
The nuclear counterstain is DAPI (blue).
Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) at 1/1000 dilution and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed (ab150120) at 1/1000 dilution (red).
The negative controls are as follows : -
-ve control 1 : ab185620 at 1/250 dilution followed by ab150120 at 1/1000 dilution.
-ve control 2 : ab7291 at 1/1000 dilution followed by ab150077 at 1/1000 dilution.
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-CDKN2A/p14ARF antibody [EPR17878] (AB185620)
Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed HeLa (Human epithelial cell line from cervix adenocarcinoma) cells transfected with CDKN2A/p14ARF-GFP labeling CDKN2A/p14ARF with ab185620 at 1/120 dilution (red) compared with a Rabbit IgG,monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti Rabbit IgG (PE) at 1/150 dilution was used as the secondary antibody.
- IP
Supplier Data
Immunoprecipitation - Anti-CDKN2A/p14ARF antibody [EPR17878] (AB185620)
CDKN2A/p14ARF was immunoprecipitated from 1mg of CDKN2A/p14ARF transfected HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate with ab185620 at 1/80 dilution.
Western blot was performed from the immunoprecipitate using ab185620 at 1/1000 dilution.
VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1 : CDKN2A/p14ARF transfected HeLa whole cell lysate, 10μg (Input).
Lane 2 : ab185620 IP in CDKN2A/p14ARF transfected HeLa whole cell lysate.
Lane 3 : Rabbit IgG,monoclonal[EPR25A] - Isotype Control (ab172730) instead of ab185620 in CDKN2A/p14ARF transfected HeLa whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 1 second.
All lanes:
Immunoprecipitation - Anti-CDKN2A/p14ARF antibody [EPR17878] (ab185620)
Predicted band size: 14 kDa
false
- WB
Lab
Western blot - Anti-CDKN2A/p14ARF antibody [EPR17878] (AB185620)
Lanes 1 - 2 : Merged signal (red and green). Green - ab185620 observed at 14 kDa. Red - loading control, ab9484, observed at 37 kDa.
ab185620 was shown to specifically react with CDKN2A/p14ARF in wild-type HeLa cells as signal was lost in CDKN2A knockout cells. Wild-type and CDKN2A knockout samples were subjected to SDS-PAGE. ab185620 and ab9484 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-CDKN2A/p14ARF antibody [EPR17878] (ab185620) at 1/1000 dilution
Lane 1:
Wild-type HeLa whole cell lysate at 20 µg
Lane 2:
CDKN2A knockout HeLa whole cell lysate at 20 µg
Predicted band size: 14 kDa
false
- WB
Supplier Data
Western blot - Anti-CDKN2A/p14ARF antibody [EPR17878] (AB185620)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-CDKN2A/p14ARF antibody [EPR17878] (ab185620) at 1/5000 dilution
Lane 1:
HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate transfected with empty vector (vector control) at 10 µg
Lane 2:
HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate transfected with CDKN2A/p14ARF with His-tag at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 14 kDa
false
Exposure time: 1s
- WB
Supplier Data
Western blot - Anti-CDKN2A/p14ARF antibody [EPR17878] (AB185620)
Blocking/Dilution buffer : 5% NFDM/TBST.
The expression level of p14 ARF is relatively low in most cell types and will be induced by oncogene expression. (PMID : 9694807; PMID : 9694806).
All lanes:
Western blot - Anti-CDKN2A/p14ARF antibody [EPR17878] (ab185620) at 1/1000 dilution
Lane 1:
PC-3 (Human prostate adenocarcinoma cell line) whole cell lysate at 20 µg
Lane 2:
HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
false
Exposure time: 3min
Related conjugates and formulations (7)
-
Anti-CDKN2A/p14ARF antibody [EPR17878] - BSA and Azide free
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-CDKN2A/p14ARF antibody [EPR17878]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-CDKN2A/p14ARF antibody [EPR17878]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-CDKN2A/p14ARF antibody [EPR17878]
-
578 PE
PE Anti-CDKN2A/p14ARF antibody [EPR17878]
-
660 APC
APC Anti-CDKN2A/p14ARF antibody [EPR17878]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-CDKN2A/p14ARF antibody [EPR17878]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (16)
Recent publications for all applications. Explore the full list and refine your search
Cancer cell international 25:325 PubMed41044576
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in immunology 16:1557848 PubMed40557159
2025
Applications
Unspecified application
Species
Unspecified reactive species
British journal of pharmacology 182:2409-2425 PubMed39933533
2025
Applications
Unspecified application
Species
Unspecified reactive species
Molecular cell 84:4538-4557.e12 PubMed39532099
2024
Applications
Unspecified application
Species
Unspecified reactive species
Discover oncology 15:519 PubMed39361158
2024
Applications
Unspecified application
Species
Unspecified reactive species
Human genomics 18:55 PubMed38822443
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of inflammation research 17:1857-1871 PubMed38523689
2024
Applications
Unspecified application
Species
Unspecified reactive species
Molecular biology reports 51:385 PubMed38438773
2024
Applications
Unspecified application
Species
Unspecified reactive species
Science advances 9:eadg7112 PubMed37595040
2023
Applications
Unspecified application
Species
Unspecified reactive species
Acta biochimica et biophysica Sinica 55:367-381 PubMed36942988
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com